

FACT SHEET

COMPANY

Foundation

2016 as PARI Pharma Spin Off

Core Business

Drug-aerosol therapeutics in pulmonary orphan indications

Specialized Skills

Drug formulation and manufacturing, drug delivery into the lungs, clinical development and go to market

Financing

Series A closed in 2017 and raised 46 million USD

LEAD ASSET

Drug Device Product

Liposomal Cyclosporine A (L-CsA) for inhalation with eFlow Nebulizer System

Indication

Bronchiolitis Obliterans Syndrome (BOS) – a fatal respiratory disease without any therapy available

Development Stage

Drug and device manufacturing at full commercial scale.

Start of two US/EU Ph 3 studies in Q1 2019

OPPORTUNITY

L-CsA for the treatment of BOS

First in class drug therapy in orphan niche market with sales potential is over 1 billion USD

BREATH prepares for own product commercialization with first sale in 2022

Pipeline

Undisclosed molecule in Pulmonary Hypertension (PH) with novel MOA for disease modifying inhalation therapy

Start non clinic H1/2019